On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
Abstract
:1. Introduction
2. Ischemic Brain Injury
3. Alzheimer’s Disease
4. Common Features of Ischemic Brain Injury and Alzheimer’s Disease
5. Wnt Signaling in Ischemic Brain Injury and Alzheimer’s Disease
6. Future Perspectives
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Katan, M.; Luft, A. Global Burden of Stroke. Semin. Neurol. 2018, 38, 208–211. [Google Scholar] [CrossRef] [Green Version]
- DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 2019, 14, 1–18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pluta, R.; Januszewski, S.; Czuczwar, S.J. Brain Ischemia as a Prelude to Alzheimer’s Disease. Front. Aging Neurosci. 2021, 13, 636653. [Google Scholar] [CrossRef] [PubMed]
- Nakagawa, T.; Hasegawa, Y.; Uekawa, K.; Senju, S.; Nakagata, N.; Matsui, K.; Kim-Mitsuyama, S. Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer’s DiseaseviaAngiotensin AT1 Receptor. Am. J. Hypertens. 2016, 30, 141–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- World Health Organization (WHO). The Top 10 Causes of Death. Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed on 4 July 2021).
- Nadarajan, V.; Perry, R.J.; Johnson, J.; Werring, D.J. Transient ischaemic attacks: Mimics and chameleons. Pract. Neurol. 2014, 14, 23–31. [Google Scholar] [CrossRef] [Green Version]
- Kirdajova, D.B.; Kriska, J.; Tureckova, J.; Anderova, M. Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells. Front. Cell. Neurosci. 2020, 14, 51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderova, M.; Vorisek, I.; Pivonkova, H.; Benesova, J.; Vargova, L.; Cicanic, M.; Chvatal, A.; Sykova, E. Cell Death/Proliferation and Alterations in Glial Morphology Contribute to Changes in Diffusivity in the Rat Hippocampus after Hypoxia—Ischemia. Br. J. Pharmacol. 2010, 31, 894–907. [Google Scholar] [CrossRef] [Green Version]
- Ferrer, I.; Planas, A.M. Signaling of Cell Death and Cell Survival Following Focal Cerebral Ischemia: Life and Death Struggle in the Penumbra. J. Neuropathol. Exp. Neurol. 2003, 62, 329–339. [Google Scholar] [CrossRef] [Green Version]
- Brouns, R.; De Deyn, P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg. 2009, 111, 483–495. [Google Scholar] [CrossRef]
- A Donnan, G.; Fisher, M.; Macleod, M.R.; Davis, S.M. Stroke. Lancet 2008, 371, 1612–1623. [Google Scholar] [CrossRef]
- Puig, B.; Brenna, S.; Magnus, T. Molecular Communication of a Dying Neuron in Stroke. Int. J. Mol. Sci. 2018, 19, 2834. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thirugnanachandran, T.; Ma, H.; Singhal, S.; Slater, L.-A.; Davis, S.M.; A Donnan, G.; Phan, T. Refining the ischemic penumbra with topography. Int. J. Stroke 2017, 13, 277–284. [Google Scholar] [CrossRef]
- Choudhury, G.R.; Ding, S. Reactive astrocytes and therapeutic potential in focal ischemic stroke. Neurobiol. Dis. 2016, 85, 234–244. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, S. Dynamic reactive astrocytes after focal ischemia. Neural Regen. Res. 2014, 9, 2048–2052. [Google Scholar] [CrossRef] [PubMed]
- Okada, S.; Hara, M.; Kobayakawa, K.; Matsumoto, Y.; Nakashima, Y. Astrocyte reactivity and astrogliosis after spinal cord injury. Neurosci. Res. 2018, 126, 39–43. [Google Scholar] [CrossRef]
- Morizawa, Y.M.; Hirayama, Y.; Ohno, N.; Shibata, S.; Shigetomi, E.; Sui, Y.; Nabekura, J.; Sato, K.; Okajima, F.; Takebayashi, H.; et al. Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. Nat. Commun. 2017, 8. [Google Scholar] [CrossRef]
- Hu, X.; Li, P.; Guo, Y.; Wang, H.; Leak, R.K.; Chen, S.; Gao, Y.; Chen, J. Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion after Focal Cerebral Ischemia. Stroke 2012, 43, 3063–3070. [Google Scholar] [CrossRef] [Green Version]
- Xu, S.; Lu, J.; Shao, A.; Zhang, J.H.; Zhang, J. Glial Cells: Role of the Immune Response in Ischemic Stroke. Front. Immunol. 2020, 11, 294. [Google Scholar] [CrossRef] [PubMed]
- Barakat, R.R.; Redzic, Z.B. The Role of Activated Microglia and Resident Macrophages in the Neurovascular Unit during Cerebral Ischemia: Is the Jury Still Out? Med. Princ. Pract. 2016, 25, 3–14. [Google Scholar] [CrossRef]
- Woodruff, T.M.; Thundyil, J.; Tang, S.-C.; Sobey, C.G.; Taylor, S.M.; Arumugam, T.V. Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Mol. Neurodegener. 2011, 6, 11–19. [Google Scholar] [CrossRef] [Green Version]
- Brouns, R.; Sheorajpanday, R.; Wauters, A.; De Surgeloose, D.; Mariën, P.; De Deyn, P.P. Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. Clin. Chim. Acta 2008, 397, 27–31. [Google Scholar] [CrossRef]
- Abramov, A.Y.; Scorziello, A.; Duchen, M. Three Distinct Mechanisms Generate Oxygen Free Radicals in Neurons and Contribute to Cell Death during Anoxia and Reoxygenation. J. Neurosci. 2007, 27, 1129–1138. [Google Scholar] [CrossRef]
- Rossi, D.J.; Brady, J.D.; Mohr, C. Astrocyte metabolism and signaling during brain ischemia. Nat. Neurosci. 2007, 10, 1377–1386. [Google Scholar] [CrossRef] [PubMed]
- Liang, D.; Bhatta, S.; Gerzanich, V.; Simard, J.M. Cytotoxic edema: Mechanisms of pathological cell swelling. Neurosurg. Focus 2007, 22, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, M.-Y.; Yiang, G.-T.; Liao, W.-T.; Tsai, A.; Cheng, Y.-L.; Cheng, P.-W.; Li, C.-Y. Current Mechanistic Concepts in Ischemia and Reperfusion Injury. Cell. Physiol. Biochem. 2018, 46, 1650–1667. [Google Scholar] [CrossRef] [PubMed]
- 2020 Alzheimer’s Disease Facts and Figures. Alzheimers Dementia. Available online: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12068 (accessed on 27 July 2021).
- Niu, H.; Álvarez-Álvarez, I.; Guillén-Grima, F.; Aguinaga-Ontoso, I. Prevalencia e incidencia de la enfermedad de Alzheimer en Europa: Metaanálisis. Neurología 2017, 32, 523–532. [Google Scholar] [CrossRef]
- Hebert, L.E.; Weuve, J.; Scherr, P.A.; Evans, D.A. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology 2013, 80, 1778–1783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prince, M.; Bryce, R.; Albanese, E.; Wimo, A.; Ribeiro, W.; Ferri, C. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s Dement. 2013, 9, 63–75. [Google Scholar] [CrossRef]
- Russ, T.C.; Batty, G.; Hearnshaw, G.F.; Fenton, C.; Starr, J.M. Geographical variation in dementia: Systematic review with meta-analysis. Int. J. Epidemiol. 2012, 41, 1012–1032. [Google Scholar] [CrossRef]
- Lopez, O.L.; Kuller, L.H. Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer’s disease and other dementias. In Handbook of Clinical Neurology; Elsevier: Amsterdam, The Netherlands, 2019; Volume 167, pp. 139–148. [Google Scholar] [CrossRef]
- Sosa-Ortiz, A.L.; Castillo, G.I.A.; Prince, M. Epidemiology of Dementias and Alzheimer’s Disease. Arch. Med. Res. 2012, 43, 600–608. [Google Scholar] [CrossRef] [PubMed]
- Chandra, V.; Ganguli, M.; Pandav, R.; Johnston, J.; Belle, S.; DeKosky, S.T. Prevalence of Alzheimer’s disease and other dementias in rural India. Neurology 1998, 51, 1000–1008. [Google Scholar] [CrossRef] [Green Version]
- Hendrie, H.C.; O Osuntokun, B.; Hall, K.S.; O Ogunniyi, A.; Hui, S.L.; Unverzagt, F.W.; Gureje, O.; A Rodenberg, C.; Baiyewu, O.; Musick, B.S. Prevalence of Alzheimer’s disease and dementia in two communities: Nigerian Africans and African Americans. Am. J. Psychiatry 1995, 152, 1485–1492. [Google Scholar] [CrossRef]
- Life expectancy. Available online: https://www.worlddata.info/life-expectancy.php (accessed on 27 July 2021).
- Frisoni, G.B.; Fox, N.C.; Clifford, R.J., Jr.; Scheltens, P.; Thompson, P. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 67–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsuda, H. MRI morphometry in Alzheimer’s disease. Ageing Res. Rev. 2016, 30, 17–24. [Google Scholar] [CrossRef] [PubMed]
- Nordberg, A.; Rinne, J.O.; Kadir, A.; Långström, B. The use of PET in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 78–87. [Google Scholar] [CrossRef]
- Duara, R.; Lopez-Alberola, R.F.; Barker, W.W.; Loewenstein, D.A.; Zatinsky, M.; Eisdorfer, C.E.; Weinberg, G.B. A comparison of familial and sporadic Alzheimer’s disease. Neurology 1993, 43, 1377. [Google Scholar] [CrossRef] [PubMed]
- Corder, E.H.; Saunders, A.M.; Strittmatter, W.J.; Schmechel, D.E.; Gaskell, P.C.; Small, G.W.; Roses, A.D.; Haines, J.L.; Pericak-Vance, M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261, 921–923. [Google Scholar] [CrossRef] [PubMed]
- Verghese, P.B.; Castellano, J.; Garai, K.; Wang, Y.; Jiang, H.; Shah, A.; Bu, G.; Frieden, C.; Holtzman, D.M. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/A association in physiological conditions. Proc. Natl. Acad. Sci. USA 2013, 110, E1807–E1816. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cerf, E.; Gustot, A.; Goormaghtigh, E.; Ruysschaert, J.-M.; Raussens, V. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer’s disease. FASEB J. 2011, 25, 1585–1595. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, R.A. Risk factors for Alzheimer’s disease. Folia Neuropathol. 2019, 57, 87–105. [Google Scholar] [CrossRef] [Green Version]
- Mendiola-Precoma, J.; Berumen, L.C.; Padilla, K.; Garcia-Alcocer, G. Therapies for Prevention and Treatment of Alzheimer’s Disease. BioMed Res. Int. 2016, 2016, 2589276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jaunmuktane, Z.; Mead, S.; Ellis, M.; Wadsworth, J.; Nicoll, A.J.; Kenny, J.; Launchbury, F.; Linehan, J.M.; Richard-Loendt, A.; Walker, A.S.; et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nat. Cell Biol. 2015, 525, 247–250. [Google Scholar] [CrossRef]
- Tarasoff-Conway, J.M.; Carare, R.O.; Osorio, R.; Glodzik, L.; Butler, T.; Fieremans, E.; Axel, L.; Rusinek, H.; Nicholson, C.; Zlokovic, B.V.; et al. Clearance systems in the brain—Implications for Alzheimer disease. Nat. Rev. Neurol. 2015, 11, 457–470. [Google Scholar] [CrossRef] [Green Version]
- Harrison, I.F.; Ismail, O.; Machhada, A.; Colgan, N.; Ohene, Y.; Nahavandi, P.; Ahmed, Z.; Fisher, A.; Meftah, S.; Murray, T.K.; et al. Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model. Brain 2020, 143, 2576–2593. [Google Scholar] [CrossRef] [PubMed]
- De Strooper, B.; Karran, E. The Cellular Phase of Alzheimer’s Disease. Cell 2016, 164, 603–615. [Google Scholar] [CrossRef] [Green Version]
- Jack, C.R.; Wiste, H.J.; Weigand, S.D.; A Rocca, W.; Knopman, D.S.; Mielke, M.; Lowe, V.J.; Senjem, M.L.; Gunter, J.L.; Preboske, G.M.; et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: A cross-sectional study. Lancet Neurol. 2014, 13, 997–1005. [Google Scholar] [CrossRef] [Green Version]
- Jack, C.R.; Wiste, H.J.; Weigand, S.D.; Therneau, T.M.; Knopman, D.S.; Lowe, V.; Vemuri, P.; Mielke, M.; O Roberts, R.; Machulda, M.M.; et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: A cross-sectional study. Lancet Neurol. 2017, 16, 435–444. [Google Scholar] [CrossRef]
- Lazarevic, V.; Fieńko, S.; Andres-Alonso, M.; Anni, D.; Ivanova, D.; Montenegro-Venegas, C.; Gundelfinger, E.; Cousin, M.; Fejtova, A. Physiological Concentrations of Amyloid Beta Regulate Recycling of Synaptic Vesicles via Alpha7 Acetylcholine Receptor and CDK5/Calcineurin Signaling. Front. Mol. Neurosci. 2017, 10, 221. [Google Scholar] [CrossRef]
- Zhang, F.; Gannon, M.; Chen, Y.; Yan, S.; Zhang, S.; Feng, W.; Tao, J.; Sha, B.; Liu, Z.; Saito, T.; et al. β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade. Sci. Transl. Med. 2020, 12, eaay6931. [Google Scholar] [CrossRef]
- Barthélemy, N.R.; Network, T.D.I.A.; Li, Y.; Joseph-Mathurin, N.; Gordon, B.A.; Hassenstab, J.; Benzinger, T.L.S.; Buckles, V.; Fagan, A.M.; Perrin, R.J.; et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat. Med. 2020, 26, 398–407. [Google Scholar] [CrossRef]
- Snyder, E.M.; Nong, Y.; Almeida, C.G.; Paul, S.; Moran, T.; Choi, E.Y.; Nairn, A.; Salter, M.W.; Lombroso, P.J.; Gouras, G.; et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 2005, 8, 1051–1058. [Google Scholar] [CrossRef]
- Shankar, G.M.; Bloodgood, B.; Townsend, M.; Walsh, D.M.; Selkoe, D.J.; Sabatini, B.L. Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway. J. Neurosci. 2007, 27, 2866–2875. [Google Scholar] [CrossRef] [PubMed]
- Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shankar, G.M.; A Kuskowski, M.; Selkoe, D.J.; Ashe, K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 2004, 8, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Walsh, M.M.; Rowan, M.J.; Selkoe, D.J.; Anwyl, R. Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type. J. Neurosci. 2004, 24, 3370–3378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, S.; Hong, S.; Shepardson, N.E.; Walsh, D.M.; Shankar, G.M.; Selkoe, D. Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake. Neuron 2009, 62, 788–801. [Google Scholar] [CrossRef] [Green Version]
- Xia, M.; Cheng, X.; Yi, R.; Gao, D.; Xiong, J. The Binding Receptors of Aβ: An Alternative Therapeutic Target for Alzheimer’s Disease. Mol. Neurobiol. 2014, 53, 455–471. [Google Scholar] [CrossRef] [PubMed]
- Benilova, I.; Karran, E.; De Strooper, B. The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nat. Neurosci. 2012, 15, 349–357. [Google Scholar] [CrossRef] [PubMed]
- Viola, K.L.; Klein, W.L. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015, 129, 183–206. [Google Scholar] [CrossRef]
- Campioni, S.; Mannini, B.; Zampagni, M.; Pensalfini, A.; Parrini, C.; Evangelisti, E.; Relini, A.; Stefani, M.; Dobson, C.M.; Cecchi, C.; et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 2010, 6, 140–147. [Google Scholar] [CrossRef]
- Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nat. Cell Biol. 2002, 416, 535–539. [Google Scholar] [CrossRef]
- Lesné, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440, 352–357. [Google Scholar] [CrossRef] [PubMed]
- Prinz, M.; Jung, S.; Priller, J. Microglia Biology: One Century of Evolving Concepts. Cell 2019, 179, 292–311. [Google Scholar] [CrossRef]
- Salter, M.W.; Beggs, S. Sublime Microglia: Expanding Roles for the Guardians of the CNS. Cell 2014, 158, 15–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Y.; Du, X.-F.; Liu, C.-S.; Wen, Z.L.; Du, J.-L. Reciprocal Regulation between Resting Microglial Dynamics and Neuronal Activity In Vivo. Dev. Cell 2012, 23, 1189–1202. [Google Scholar] [CrossRef] [Green Version]
- Thériault, P.; ElAli, A.; Rivest, S. The dynamics of monocytes and microglia in Alzheimer’s disease. Alzheimer’s Res. Ther. 2015, 7, 1–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serrano-Pozo, A.; Muzikansky, A.; Gómez-Isla, T.; Growdon, J.H.; Betensky, R.A.; Frosch, M.P.; Hyman, B.T. Differential Relationships of Reactive Astrocytes and Microglia to Fibrillar Amyloid Deposits in Alzheimer Disease. J. Neuropathol. Exp. Neurol. 2013, 72, 462–471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goetzl, E.J.; Miller, B.L. Multicellular hypothesis for the pathogenesis of Alzheimer’s disease. FASEB J. 2017, 31, 1792–1795. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Babcock, A.A.; Ilkjær, L.; Clausen, B.H.; Villadsen, B.; Dissing-Olesen, L.; Bendixen, A.T.; Lyck, L.; Lambertsen, K.L.; Finsen, B. Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. Brain Behav. Immun. 2015, 48, 86–101. [Google Scholar] [CrossRef]
- Orre, M.; Kamphuis, W.; Dooves, S.; Kooijman, L.; Chan, E.T.; Kirk, C.J.; Smith, V.D.; Koot, S.; Mamber, C.; Jansen, A.H.; et al. Reactive glia show increased immunoproteasome activity in Alzheimer’s disease. Brain 2013, 136, 1415–1431. [Google Scholar] [CrossRef] [Green Version]
- Esolito, E.; Esastre, M. Microglia Function in Alzheimer’s Disease. Front. Pharmacol. 2012, 3, 14. [Google Scholar] [CrossRef] [Green Version]
- Yong, V.W.; Moumdjian, R.; Yong, F.P.; Ruijs, T.C.; Freedman, M.S.; Cashman, N.; Antel, J. Gamma-interferon promotes proliferation of adult human astrocytes in vitro and reactive gliosis in the adult mouse brain in vivo. Proc. Natl. Acad. Sci. USA 1991, 88, 7016–7020. [Google Scholar] [CrossRef] [Green Version]
- Blasko, I.; Veerhuis, R.; Stampfer-Kountchev, M.; Saurwein-Teissl, M.; Eikelenboom, P.; Grubeck-Loebenstein, B. Costimulatory Effects of Interferon-γ and Interleukin-1β or Tumor Necrosis Factor α on the Synthesis of Aβ1-40 and Aβ1-42 by Human Astrocytes. Neurobiol. Dis. 2000, 7, 682–689. [Google Scholar] [CrossRef] [Green Version]
- Kleinberger, G.; Yamanishi, Y.; Suárez-Calvet, M.; Czirr, E.; Lohmann, E.; Cuyvers, E.; Struyfs, H.; Pettkus, N.; Wenninger-Weinzierl, A.; Mazaheri, F.; et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 2014, 6, 243ra86. [Google Scholar] [CrossRef]
- Griciuc, A.; Serrano-Pozo, A.; Parrado, A.R.; Lesinski, A.N.; Asselin, C.N.; Mullin, K.; Hooli, B.; Choi, S.H.; Hyman, B.T.; Tanzi, R.E. Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron 2013, 78, 631–643. [Google Scholar] [CrossRef] [Green Version]
- Heneka, M.T.; Carson, M.J.; El Khoury, J.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015, 14, 388–405. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Cui, G.; Zhu, M.; Kang, X.; Guo, H. Neuroinflammation in Alzheimer’s disease: Chemokines produced by astrocytes and chemokine receptors. Int. J. Clin. Exp. Pathol. 2014, 7, 8342–8355. [Google Scholar] [PubMed]
- Goetzl, E.J.; Mustapic, M.; Kapogiannis, D.; Eitan, E.; Lobach, I.V.; Goetzl, L.; Schwartz, J.B.; Miller, B.L. Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer’s disease. FASEB J. 2016, 30, 3853–3859. [Google Scholar] [CrossRef] [Green Version]
- Haj-Yasein, N.N.; Vindedal, G.F.; Eilert-Olsen, M.; Gundersen, G.A.; Skare, Ø.; Laake, P.; Klungland, A.; Thorén, A.E.; Burkhardt, J.M.; Ottersen, O.P.; et al. Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood-brain water uptake and confers barrier function on perivascular astrocyte endfeet. Proc. Natl. Acad. Sci. USA 2011, 108, 17815–17820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lan, Y.-L.; Zhao, J.; Ma, T.; Li, S. The Potential Roles of Aquaporin 4 in Alzheimer’s Disease. Mol. Neurobiol. 2016, 53, 5300–5309. [Google Scholar] [CrossRef]
- Valenza, M.; Facchinetti, R.; Steardo, L.; Scuderi, C. Altered Waste Disposal System in Aging and Alzheimer’s Disease: Focus on Astrocytic Aquaporin. Front Pharmacol. 2020, 10, 1656. [Google Scholar] [CrossRef]
- Iram, T.; Trudler, D.; Kain, D.; Kanner, S.; Galron, R.; Vassar, R.; Barzilai, A.; Blinder, P.; Fishelson, Z.; Frenkel, D. Astrocytes from old Alzheimer’s disease mice are impaired in Aβ uptake and in neuroprotection. Neurobiol. Dis. 2016, 96, 84–94. [Google Scholar] [CrossRef] [PubMed]
- Hynd, M.R.; Scott, H.L.; Dodd, P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem. Int. 2004, 45, 583–595. [Google Scholar] [CrossRef] [PubMed]
- Assefa, B.T.; Gebre, A.K.; Altaye, B.M. Reactive Astrocytes as Drug Target in Alzheimer’s Disease. BioMed Res. Int. 2018, 2018, 4160247. [Google Scholar] [CrossRef] [Green Version]
- Acosta, C.; Anderson, H.D.; Anderson, C.M. Astrocyte dysfunction in Alzheimer disease. J. Neurosci. Res. 2017, 95, 2430–2447. [Google Scholar] [CrossRef]
- Bartzokis, G. Alzheimer’s disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2011, 32, 1341–1371. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Behrendt, G.; Baer, K.; Buffo, A.; Curtis, M.; Faull, R.; Rees, M.; Götz, M.; Dimou, L. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia 2013, 61, 273–286. [Google Scholar] [CrossRef] [PubMed]
- Desai, M.K.; Mastrangelo, M.A.; Ryan, D.; Sudol, K.L.; Narrow, W.C.; Bowers, W.J. Early Oligodendrocyte/Myelin Pathology in Alzheimer’s Disease Mice Constitutes a Novel Therapeutic Target. Am. J. Pathol. 2010, 177, 1422–1435. [Google Scholar] [CrossRef]
- Lall, R.; Mohammed, R.; Ojha, U. What are the links between hypoxia and Alzheimer’s disease? Neuropsychiatr. Dis. Treat. 2019, ume 15, 1343–1354. [Google Scholar] [CrossRef] [Green Version]
- Silva, M.V.F.; Loures, C.D.M.G.; Alves, L.C.V.; De Souza, L.C.; Borges, K.B.G.; Carvalho, M.D.G. Alzheimer’s disease: Risk factors and potentially protective measures. J. Biomed. Sci. 2019, 26, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Huang, H.-D.; Yang, C.-M.; Shu, H.-F.; Kuang, Y.-Q.; Yang, T.; He, W.-Q.; Zhao, K.; Xia, X.; Cheng, J.-M.; Ma, Y.; et al. Genetic predisposition of stroke: Understanding the evolving landscape through meta-analysis. Int. J. Clin. Exp. Med. 2015, 8, 1315–1323. [Google Scholar]
- Chauhan, G.; Debette, S. Genetic Risk Factors for Ischemic and Hemorrhagic Stroke. Curr. Cardiol. Rep. 2016, 18, 124. [Google Scholar] [CrossRef] [Green Version]
- Rosenberg, G.A. Understanding aging effects on brain ischemia. Neurobiol. Dis. 2019, 126, 3–4. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Shan, W.; Zuo, Z. Age-Related Upregulation of Carboxyl Terminal Modulator Protein Contributes to the Decreased Brain Ischemic Tolerance in Older Rats. Mol. Neurobiol. 2017, 55, 6145–6154. [Google Scholar] [CrossRef] [PubMed]
- Cortes-Canteli, M.; Iadecola, C. Alzheimer’s Disease and Vascular Aging. J. Am. Coll. Cardiol. 2020, 75, 942–951. [Google Scholar] [CrossRef] [PubMed]
- Sengoku, R. Aging and Alzheimer’s disease pathology. Neuropathology 2019, 40, 22–29. [Google Scholar] [CrossRef] [PubMed]
- Habib, N.; McCabe, C.; Medina, S.; Varshavsky, M.; Kitsberg, D.; Dvir-Szternfeld, R.; Green, G.; Dionne, D.; Nguyen, L.; Marshall, J.L.; et al. Disease-associated astrocytes in Alzheimer’s disease and aging. Nat. Neurosci. 2020, 23, 701–706. [Google Scholar] [CrossRef] [PubMed]
- Yassine, H.N.; Finch, C.E. APOE Alleles and Diet in Brain Aging and Alzheimer’s Disease. Front. Aging Neurosci. 2020, 12, 150. [Google Scholar] [CrossRef]
- Pan, B.; Jin, X.; Jun, L.; Qiu, S.; Zheng, Q.; Pan, M. The relationship between smoking and stroke. Medicine 2019, 98, e14872. [Google Scholar] [CrossRef] [PubMed]
- Wallin, C.; Sholts, S.B.; Österlund, N.; Luo, J.; Jarvet, J.; Roos, P.M.; Ilag, L.; Gräslund, A.; Wärmländer, S.K.T.S. Alzheimer’s disease and cigarette smoke components: Effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-β peptide aggregation. Sci. Rep. 2017, 7, 14423. [Google Scholar] [CrossRef] [Green Version]
- Ułamek-Kozioł, M.; Pluta, R.; Januszewski, S.; Kocki, J.; Bogucka-Kocka, A.; Czuczwar, S.J. Expression of Alzheimer’s disease risk genes in ischemic brain degeneration. Pharmacol. Rep. 2016, 68, 1345–1349. [Google Scholar] [CrossRef]
- Ułamek-Kozioł, M.; Pluta, R.; Bogucka-Kocka, A.; Januszewski, S.; Kocki, J.; Czuczwar, S.J. Brain ischemia with Alzheimer phenotype dysregulates Alzheimer’s disease-related proteins. Pharmacol. Rep. 2016, 68, 582–591. [Google Scholar] [CrossRef]
- Pluta, R.; Ułamek-Kozioł, M.; Januszewski, S.; Czuczwar, S.J. Participation of Amyloid and Tau Protein in Neuronal Death and Neurodegeneration after Brain Ischemia. Int. J. Mol. Sci. 2020, 21, 4599. [Google Scholar] [CrossRef] [PubMed]
- Badan, I.; Dinca, I.; Buchhold, B.; Suofu, Y.; Walker, L.; Gratz, M.; Platt, D.H.; Kessler, C.H.; Popa-Wagner, A. Accelerated accumulation of N- and C-terminal betaAPP fragments and delayed recovery of microtubule-associated protein 1B expression following stroke in aged rats. Eur. J. Neurosci. 2004, 19, 2270–2280. [Google Scholar] [CrossRef]
- Shi, J.; Yang, S.; Stubley, L.; Day, A.; Simpkins, J. Hypoperfusion induces overexpression of β-amyloid precursor protein mRNA in a focal ischemic rodent model. Brain Res. 2000, 853, 1–4. [Google Scholar] [CrossRef]
- Pluta, R.; Januszewski, S.; Jabłoński, M.; Ułamek, M. Factors in Creepy Delayed Neuronal Death in Hippocampus Following Brain Ischemia–Reperfusion Injury with Long-Term Survival. In Brain Edema XIV; Springer: Vienna, Austria, 2010; Volume 106, pp. 37–41. [Google Scholar] [CrossRef]
- Qi, J.-P.; Wu, H.; Yang, Y.; Wang, D.-D.; Chen, Y.-X.; Gu, Y.-H.; Liu, T. Cerebral Ischemia and Alzheimer’s Disease: The Expression of Amyloid-β and Apolipoprotein E in Human Hippocampus. J. Alzheimer’s Dis. 2007, 12, 335–341. [Google Scholar] [CrossRef] [PubMed]
- Blumenau, S.; Foddis, M.; Müller, S.; Holtgrewe, M.; Bentele, K.; Berchtold, D.; Beule, D.; Dirnagl, U.; Sassi, C. Investigating APOE, APP-Aβ metabolism genes and Alzheimer’s disease GWAS hits in brain small vessel ischemic disease. Sci. Rep. 2020, 10, 7103. [Google Scholar] [CrossRef]
- Pluta, R.; Ułamek-Kozioł, M.; Januszewski, S.; Sciślewska, M.; Bogucka-Kocka, A.; Kocki, J. Alzheimer’s factors in postischemic dementia. Rom. J. Morphol. Embryol. 2012, 53, 461–466. [Google Scholar] [PubMed]
- Pluta, R.; Ułamek-Kozioł, M.; Januszewski, S.; Czuczwar, S.J. Tau Protein Dysfunction after Brain Ischemia. J. Alzheimer’s Dis. 2018, 66, 429–437. [Google Scholar] [CrossRef] [Green Version]
- Pluta, R.; Bogucka-Kocka, A.; Ułamek-Kozioł, M.; Bogucki, J.; Januszewski, S.; Kocki, J.; Czuczwar, S.J. Ischemic tau protein gene induction as an additional key factor driving development of Alzheimer’s phenotype changes in CA1 area of hippocampus in an ischemic model of Alzheimer’s disease. Pharmacol. Rep. 2018, 70, 881–884. [Google Scholar] [CrossRef] [PubMed]
- Pluta, R. Astroglial Expression of the β-Amyloid in Ischemia-Reperfusion Brain Injury. Ann. N. Y. Acad. Sci. 2002, 977, 102–108. [Google Scholar] [CrossRef]
- Guo, C.-Y.; Xiong, T.-Q.; Tan, B.-H.; Gui, Y.; Ye, N.; Li, S.-L.; Li, Y.-C. The temporal and spatial changes of actin cytoskeleton in the hippocampal CA1 neurons following transient global ischemia. Brain Res. 2019, 1720, 146297. [Google Scholar] [CrossRef] [PubMed]
- Takuma, K.; Baba, A.; Matsuda, T. Astrocyte apoptosis: Implications for neuroprotection. Prog. Neurobiol. 2004, 72, 111–127. [Google Scholar] [CrossRef] [PubMed]
- Milewski, K.; Bogacińska-Karaś, M.; Hilgier, W.; Albrecht, J.; Zielińska, M. TNFα increases STAT3-mediated expression of glutaminase isoform KGA in cultured rat astrocytes. Cytokine 2019, 123, 154774. [Google Scholar] [CrossRef] [PubMed]
- Gülke, E.; Gelderblom, M.; Magnus, T. Danger signals in stroke and their role on microglia activation after ischemia. Ther. Adv. Neurol. Disord. 2018, 11, 1756286418774254. [Google Scholar] [CrossRef] [Green Version]
- Koistinaho, M.; Koistinaho, J. Interactions between Alzheimer’s disease and cerebral ischemia—Focus on inflammation. Brain Res. Rev. 2005, 48, 240–250. [Google Scholar] [CrossRef]
- Radenovic, L.; Nenadic, M.; Ułamek-Kozioł, M.; Januszewski, S.; Czuczwar, S.J.; Andjus, P.R.; Pluta, R. Heterogeneity in brain distribution of activated microglia and astrocytes in a rat ischemic model of Alzheimer’s disease after 2 years of survival. Aging 2020, 12, 12251–12267. [Google Scholar] [CrossRef]
- Valny, M.; Honsa, P.; Kriska, J.; Anderova, M. Multipotency and therapeutic potential of NG2 cells. Biochem. Pharmacol. 2017, 141, 42–55. [Google Scholar] [CrossRef]
- Kirdajova, D.; Valihrach, L.; Valny, M.; Kriska, J.; Krocianova, D.; Benesova, S.; Abaffy, P.; Zucha, D.; Klassen, R.; Kolenicova, D.; et al. Transient astrocyte-like NG2 glia subpopulation emerges solely following permanent brain ischemia. Glia 2021. [Google Scholar] [CrossRef]
- Valny, M.; Honsa, P.; Waloschkova, E.; Matuskova, H.; Kriska, J.; Kirdajova, D.; Androvic, P.; Valihrach, L.; Kubista, M.; Anderova, M. A single-cell analysis reveals multiple roles of oligodendroglial lineage cells during post-ischemic regeneration. Glia 2018, 66, 1068–1081. [Google Scholar] [CrossRef]
- Honsa, P.; Valny, M.; Kriska, J.; Matuskova, H.; Harantova, L.; Kirdajova, D.; Valihrach, L.; Androvic, P.; Kubista, M.; Anderova, M. Generation of reactive astrocytes from NG2 cells is regulated by sonic hedgehog. Glia 2016, 64, 1518–1531. [Google Scholar] [CrossRef]
- Doyle, S.; Hansen, D.B.; Vella, J.; Bond, P.; Harper, G.; Zammit, C.; Valentino, M.; Fern, R. Vesicular glutamate release from central axons contributes to myelin damage. Nat. Commun. 2018, 9, 1032. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nasrabady, S.E.; Rizvi, B.; Goldman, J.E.; Brickman, A.M. White matter changes in Alzheimer’s disease: A focus on myelin and oligodendrocytes. Acta Neuropathol. Commun. 2018, 6, 1–10. [Google Scholar] [CrossRef]
- Veeresh, P.; Kaur, H.; Sarmah, D.; Mounica, L.; Verma, G.; Kotian, V.; Kesharwani, R.; Kalia, K.; Borah, A.; Wang, X.; et al. Endoplasmic reticulum–mitochondria crosstalk: From junction to function across neurological disorders. Ann. N. Y. Acad. Sci. 2019, 1457, 41–60. [Google Scholar] [CrossRef]
- Tang, Y.-C.; Tian, H.-X.; Yi, T.; Chen, H.-B. The critical roles of mitophagy in cerebral ischemia. Protein Cell 2016, 7, 699–713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shao, Z.; Dou, S.; Zhu, J.; Wang, H.; Xu, D.; Wang, C.; Cheng, B.; Bai, B. The Role of Mitophagy in Ischemic Stroke. Front. Neurol. 2020, 11, 608610. [Google Scholar] [CrossRef] [PubMed]
- Reddy, P.H.; Oliver, D.M. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease. Cells 2019, 8, 488. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fang, E.F.; Hou, Y.; Palikaras, K.; Adriaanse, B.A.; Kerr, J.S.; Yang, B.; Lautrup, S.; Hasan-Olive, M.M.; Caponio, D.; Dan, X.; et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat. Neurosci. 2019, 22, 401–412. [Google Scholar] [CrossRef] [PubMed]
- Kolenicova, D.; Tureckova, J.; Pukajova, B.; Harantova, L.; Kriska, J.; Kirdajova, D.; Vorisek, I.; Kamenicka, M.; Valihrach, L.; Androvic, P.; et al. High potassium exposure reveals the altered ability of astrocytes to regulate their volume in the aged hippocampus of GFAP/EGFP mice. Neurobiol. Aging 2020, 86, 162–181. [Google Scholar] [CrossRef]
- Tannenberg, R.; Scott, H.; Westphalen, R.; Dodd, P. The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease. Curr. Alzheimer Res. 2004, 1, 11–25. [Google Scholar] [CrossRef] [PubMed]
- Wang, R.; Reddy, P.H. Role of Glutamate and NMDA Receptors in Alzheimer’s Disease. J. Alzheimer’s Dis. 2017, 57, 1041–1048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, J.; Chang, L.; Song, Y.; Li, H.; Wu, Y. The Role of NMDA Receptors in Alzheimer’s Disease. Front. Neurosci. 2019, 13, 43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kulijewicz-Nawrot, M.; Syková, E.; Chvatal, A.; Verkhratsky, A.; Rodríguez, J.J. Astrocytes and Glutamate Homoeostasis in Alzheimer’s Disease: A Decrease in Glutamine Synthetase, But Not in Glutamate Transporter-1, in the Prefrontal Cortex. ASN Neuro 2013, 5. [Google Scholar] [CrossRef] [PubMed]
- Esposito, Z.; Belli, L.; Toniolo, S.; Sancesario, G.; Bianconi, C.; Martorana, A. Amyloid β, Glutamate, Excitotoxicity in Alzheimer’s Disease: Are We on the Right Track? CNS Neurosci. Ther. 2013, 19, 549–555. [Google Scholar] [CrossRef] [PubMed]
- Rossi, D.J.; Oshima, T.; Attwell, D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nat. Cell Biol. 2000, 403, 316–321. [Google Scholar] [CrossRef]
- Setti, S.E.; Hunsberger, H.C.; Reed, M.N. Alterations in hippocampal activity and Alzheimer’s disease. Transl. Issues Psychol. Sci. 2017, 3, 348–356. [Google Scholar] [CrossRef]
- Costea, L.; Mészáros, Á.; Bauer, H.; Bauer, H.-C.; Traweger, A.; Wilhelm, I.; Farkas, A.E.; Krizbai, I.A. The Blood–Brain Barrier and Its Intercellular Junctions in Age-Related Brain Disorders. Int. J. Mol. Sci. 2019, 20, 5472. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Zhong, W.; Jiang, Z.; Tang, X. New progress in the approaches for blood–brain barrier protection in acute ischemic stroke. Brain Res. Bull. 2019, 144, 46–57. [Google Scholar] [CrossRef]
- Jiang, X.; Andjelkovic, A.V.; Zhu, L.; Yang, T.; Bennett, M.V.L.; Chen, J.; Keep, R.F.; Shi, Y. Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog. Neurobiol. 2018, 163–164, 144–171. [Google Scholar] [CrossRef] [PubMed]
- Kowalski, R.G.; Haarbauer-Krupa, J.K.; Bell, J.M.; Corrigan, J.D.; Hammond, F.M.; Torbey, M.T.; Hofmann, M.C.; Dams-O’Connor, K.; Miller, A.C.; Whiteneck, G.G. Acute Ischemic Stroke after Moderate to Severe Traumatic Brain Injury. Stroke 2017, 48, 1802–1809. [Google Scholar] [CrossRef] [Green Version]
- Abrahamson, E.E.; Ikonomovic, M.D. Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia. Exp. Neurol. 2020, 328, 113257. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Ma, S.; Hu, Z.; McGuire, T.F.; Xie, X.-Q. Chemogenomics Systems Pharmacology Mapping of Potential Drug Targets for Treatment of Traumatic Brain Injury. J. Neurotrauma 2019, 36, 565–575. [Google Scholar] [CrossRef]
- Nagelhus, E.A.; Ottersen, O.P. Physiological Roles of Aquaporin-4 in Brain. Physiol. Rev. 2013, 93, 1543–1562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Benfenati, V.; Caprini, M.; Dovizio, M.; Mylonakou, M.N.; Ferroni, S.; Ottersen, O.P.; Amiry-Moghaddam, M. An aquaporin-4/transient receptor potential vanilloid 4 (AQP4/TRPV4) complex is essential for cell-volume control in astrocytes. Proc. Natl. Acad. Sci. USA 2011, 108, 2563–2568. [Google Scholar] [CrossRef] [Green Version]
- Tourdias, T.; Mori, N.; Dragonu, I.; Cassagno, N.; Boiziau, C.; Aussudre, J.; Brochet, B.; Moonen, C.; Petry, K.G.; Dousset, V. Differential aquaporin 4 expression during edema build-up and resolution phases of brain inflammation. J. Neuroinflamm. 2011, 8, 143. [Google Scholar] [CrossRef]
- Butenko, O.; Dzamba, D.; Benesova, J.; Honsa, P.; Benfenati, V.; Rusnakova, V.; Ferroni, S.; Anderova, M. The Increased Activity of TRPV4 Channel in the Astrocytes of the Adult Rat Hippocampus after Cerebral Hypoxia/Ischemia. PLoS ONE 2012, 7, e39959. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.C.; Choe, S.Y. Age-related changes in the distribution of transient receptor potential vanilloid 4 channel (TRPV4) in the central nervous system of rats. J. Mol. Histol. 2014, 45, 497–505. [Google Scholar] [CrossRef] [PubMed]
- Liu, N.; Yan, F.; Ma, Q.; Zhao, J. Modulation of TRPV4 and BKCa for treatment of brain diseases. Bioorg. Med. Chem. 2020, 28, 115609. [Google Scholar] [CrossRef]
- Lamus, F.; Martín, C.; Carnicero, E.; Moro, J.; Fernández, J.; Mano, A.; Gato, Á.; Alonso, M.I. FGF2/EGF contributes to brain neuroepithelial precursor proliferation and neurogenesis in rat embryos: The involvement of embryonic cerebrospinal fluid. Dev. Dyn. 2019, 249, 141–153. [Google Scholar] [CrossRef]
- Ho, D.M.; Artavanis-Tsakonas, S.; Louvi, A. The Notch pathway in CNS homeostasis and neurodegeneration. Wiley Interdiscip. Rev. Dev. Biol. 2020, 9, e358. [Google Scholar] [CrossRef]
- Eskandari, S.; Sajadimajd, S.; Alaei, L.; Soheilikhah, Z.; Derakhshankhah, H.; Bahrami, G. Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer’s: A Comprehensive Review. Neurotox. Res. 2021, 1–24. [Google Scholar] [CrossRef]
- Rakers, C.; Schleif, M.; Blank, N.; Matušková, H.; Ulas, T.; Händler, K.; Torres, S.V.; Schumacher, T.; Tai, K.; Schultze, J.L.; et al. Stroke target identification guided by astrocyte transcriptome analysis. Glia 2019, 67, 619–633. [Google Scholar] [CrossRef] [PubMed]
- Reichenbach, N.; Delekate, A.; Plescher, M.; Schmitt, F.; Krauss, S.; Blank, N.; Halle, A.; Petzold, G.C. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer’s disease model. EMBO Mol. Med. 2019, 11, e9665. [Google Scholar] [CrossRef]
- Gruber, J.; Yee, Z.; Tolwinski, N.S. Developmental Drift and the Role of Wnt Signaling in Aging. Cancers 2016, 8, 73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palomer, E.; Buechler, J.; Salinas, P.C. Wnt Signaling Deregulation in the Aging and Alzheimer’s Brain. Front. Cell. Neurosci. 2019, 13, 227. [Google Scholar] [CrossRef]
- Masckauchán, T.N.H.; Shawber, C.J.; Funahashi, Y.; Li, C.-M.; Kitajewski, J. Wnt/β-Catenin Signaling Induces Proliferation, Survival and Interleukin-8 in Human Endothelial Cells. Angiogenesis 2005, 8, 43–51. [Google Scholar] [CrossRef] [PubMed]
- Kriska, J.; Janeckova, L.; Kirdajova, D.; Honsa, P.; Knotek, T.; Dzamba, D.; Kolenicova, D.; Butenko, O.; Vojtechova, M.; Capek, M.; et al. Wnt/β-Catenin Signaling Promotes Differentiation of Ischemia-Activated Adult Neural Stem/Progenitor Cells to Neuronal Precursors. Front. Neurosci. 2021, 15, 628983. [Google Scholar] [CrossRef] [PubMed]
- Kriska, J.; Honsa, P.; Dzamba, D.; Butenko, O.; Kolenicova, D.; Janeckova, L.; Nahacka, Z.; Andera, L.; Kozmik, Z.; Taketo, M.M.; et al. Manipulating Wnt signaling at different subcellular levels affects the fate of neonatal neural stem/progenitor cells. Brain Res. 2016, 1651, 73–87. [Google Scholar] [CrossRef]
- Kuwabara, T.; Hsieh, J.; Muotri, A.; Yeo, E.; Warashina, M.; Lie, D.C.; Moore, L.; Nakashima, K.; Asashima, M.; Gage, F.H. Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nat. Neurosci. 2009, 12, 1097–1105. [Google Scholar] [CrossRef] [Green Version]
- Hartung, N.; Benary, U.; Wolf, J.; Kofahl, B. Paracrine and autocrine regulation of gene expression by Wnt-inhibitor Dickkopf in wild-type and mutant hepatocytes. BMC Syst. Biol. 2017, 11, 98. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Katoh, M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int. J. Oncol. 2017, 51, 1357–1369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Herreros, A.G.; Duñach, M.; De Herreros, G. Intracellular Signals Activated by Canonical Wnt Ligands Independent of GSK3 Inhibition and β-Catenin Stabilization. Cells 2019, 8, 1148. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Flores-Hernández, E.; Velázquez, D.M.; Castañeda-Patlán, M.C.; Fuentes-García, G.; Fonseca-Camarillo, G.; Yamamoto-Furusho, J.K.; Romero-Avila, M.T.; García-Sáinz, J.A.; Robles-Flores, M. Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. Cell. Signal. 2020, 72, 109636. [Google Scholar] [CrossRef] [PubMed]
- Gao, C.; Chen, Y.-G. Dishevelled: The hub of Wnt signaling. Cell. Signal. 2010, 22, 717–727. [Google Scholar] [CrossRef]
- Nusse, R.; Clevers, H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell 2017, 169, 985–999. [Google Scholar] [CrossRef]
- Green, J.; Nusse, R.; Van Amerongen, R. The Role of Ryk and Ror Receptor Tyrosine Kinases in Wnt Signal Transduction. Cold Spring Harb. Perspect. Biol. 2014, 6, a009175. [Google Scholar] [CrossRef]
- Ameyar, M.; Wisniewska, M.; Weitzman, J. A role for AP-1 in apoptosis: The case for and against. Biochimie 2003, 85, 747–752. [Google Scholar] [CrossRef]
- Vandervorst, K.; Dreyer, C.A.; Konopelski, S.E.; Lee, H.; Ho, H.-Y.H.; Carraway, K.L. Wnt/PCP Signaling Contribution to Carcinoma Collective Cell Migration and Metastasis. Cancer Res. 2019, 79, 1719–1729. [Google Scholar] [CrossRef] [Green Version]
- Knotek, T.; Janeckova, L.; Kriska, J.; Korinek, V.; Anderova, M. Glia and Neural Stem and Progenitor Cells of the Healthy and Ischemic Brain: The Workplace for the Wnt Signaling Pathway. Genes 2020, 11, 804. [Google Scholar] [CrossRef]
- Martínez, M.; Inestrosa, N.C. The transcriptional landscape of Alzheimer’s disease and its association with Wnt signaling pathway. Neurosci. Biobehav. Rev. 2021, 128, 454–466. [Google Scholar] [CrossRef] [PubMed]
- Taciak, B.; Pruszynska, I.; Kiraga, L.; Bialasek, M.; Krol, M. Wnt signaling pathway in development and cancer. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2018, 69, 185–196. [Google Scholar]
- Liang, C.-J.; Wang, Z.-W.; Chang, Y.-W.; Lee, K.-C.; Lin, W.-H.; Lee, J.-L. SFRPs Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties beyond Extracellular Control. Cell Rep. 2019, 28, 1511–1525. [Google Scholar] [CrossRef] [Green Version]
- Semënov, M.V.; Zhang, X.; He, X. DKK1 Antagonizes Wnt Signaling without Promotion of LRP6 Internalization and Degradation. J. Biol. Chem. 2008, 283, 21427–21432. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jia, L.; Piña-Crespo, J.; Li, Y. Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease. Mol. Brain 2019, 12, 1–11. [Google Scholar] [CrossRef]
- Xia, M.-Y.; Zhao, X.-Y.; Huang, Q.-L.; Sun, H.-Y.; Sun, C.; Yuan, J.; He, C.; Sun, Y.; Huang, X.; Kong, W.; et al. Activation of Wnt/β-catenin signaling by lithium chloride attenuatesd-galactose-induced neurodegeneration in the auditory cortex of a rat model of aging. FEBS Open Bio 2017, 7, 759–776. [Google Scholar] [CrossRef] [PubMed]
- Inestrosa, N.C.; de Ferrari, G.V.; Garrido, J.L.; Alvarez, A.; Olivares, G.; Barría, M.I.; Bronfman, M.; A Chacón, M. Wnt signaling involvement in β-amyloid-dependent neurodegeneration. Neurochem. Int. 2002, 41, 341–344. [Google Scholar] [CrossRef]
- Inestrosa, N.C.; Rojas, C.T. Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer’s disease. Neural Regen. Res. 2018, 13, 1705–1710. [Google Scholar] [CrossRef]
- Libro, R.; Bramanti, P.; Mazzon, E. The role of the Wnt canonical signaling in neurodegenerative diseases. Life Sci. 2016, 158, 78–88. [Google Scholar] [CrossRef]
- Zhan, L.; Liu, D.; Wen, H.; Hu, J.; Pang, T.; Sun, W.; Xu, E. Hypoxic postconditioning activates the Wnt/β-catenin pathway and protects against transient global cerebral ischemia through Dkk1 Inhibition and GSK-3β inactivation. FASEB J. 2019, 33, 9291–9307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oliva, C.; Vargas, J.Y.; Inestrosa, N.C. Wnt signaling: Role in LTP, neural networks and memory. Ageing Res. Rev. 2013, 12, 786–800. [Google Scholar] [CrossRef]
- Jansen, O.; Rohr, A. Neurothrombectomy in the treatment of acute ischaemic stroke. Nat. Rev. Neurol. 2013, 9, 645–652. [Google Scholar] [CrossRef]
- Mastroiacovo, F.; Busceti, C.L.; Biagioni, F.; Moyanova, S.; Meisler, M.H.; Battaglia, G.; Caricasole, A.; Bruno, V.M.G.; Nicoletti, F. Induction of the Wnt Antagonist, Dickkopf-1, Contributes to the Development of Neuronal Death in Models of Brain Focal Ischemia. Br. J. Pharmacol. 2008, 29, 264–276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Q.; Dashwood, W.M.; Zhong, X.; Nakagama, H.; Dashwood, R.H. Bcl-2 overexpression in PhIP-induced colon tumors: Cloning of the rat Bcl-2 promoter and characterization of a pathway involving β-catenin, c-Myc and E2F. Oncogene 2007, 26, 6194–6202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seifert-Held, T.; Pekar, T.; Gattringer, T.; Simmet, N.E.; Scharnagl, H.; Stojakovic, T.; Fazekas, F.; Storch, M.K. Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease. Atherosclerosis 2011, 218, 233–237. [Google Scholar] [CrossRef] [PubMed]
- He, X.-W.; Wang, E.; Bao, Y.-Y.; Wang, F.; Zhu, M.; Hu, X.-F.; Jin, X.-P. High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke. Atherosclerosis 2016, 253, 22–28. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Zhang, J.; Qi, C.; Yang, P.; Chen, X.; Liu, Y. Activation of Wnt3α/β-catenin signal pathway attenuates apoptosis of the cerebral microvascular endothelial cells induced by oxygen-glucose deprivation. Biochem. Biophys. Res. Commun. 2017, 490, 71–77. [Google Scholar] [CrossRef]
- Chacón, M.A.; Varela-Nallar, L.; Inestrosa, N.C. Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Aβ oligomers. J. Cell. Physiol. 2008, 217, 215–227. [Google Scholar] [CrossRef]
- Abe, T.; Zhou, P.; Jackman, K.; Capone, C.; Casolla, B.; Hochrainer, K.; Kahles, T.; Ross, M.E.; Anrather, J.; Iadecola, C. Lipoprotein Receptor–Related Protein-6 Protects the Brain from Ischemic Injury. Stroke 2013, 44, 2284–2291. [Google Scholar] [CrossRef] [Green Version]
- Zhou, X.; Zhou, J.; Li, X.; Guo, C.; Fang, T.; Chen, Z. GSK-3β inhibitors suppressed neuroinflammation in rat cortex by activating autophagy in ischemic brain injury. Biochem. Biophys. Res. Commun. 2011, 411, 271–275. [Google Scholar] [CrossRef]
- Hurn, P.D.; Macrae, I.M. Estrogen as a Neuroprotectant in Stroke. Br. J. Pharmacol. 2000, 20, 631–652. [Google Scholar] [CrossRef]
- Scott, E.L.; Brann, D.W. Estrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease. Brain Res. 2013, 1514, 63–74. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Q.-G.; Wang, R.; Khan, M.; Mahesh, V.; Brann, D.W. Role of Dickkopf-1, an Antagonist of the Wnt/β-Catenin Signaling Pathway, in Estrogen-Induced Neuroprotection and Attenuation of Tau Phosphorylation. J. Neurosci. 2008, 28, 8430–8441. [Google Scholar] [CrossRef] [PubMed]
- Boldrini, M.; Fulmore, C.A.; Tartt, A.N.; Simeon, L.R.; Pavlova, I.; Poposka, V.; Rosoklija, G.B.; Stankov, A.; Arango, V.; Dwork, A.J.; et al. Human Hippocampal Neurogenesis Persists throughout Aging. Cell Stem Cell 2018, 22, 589–599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, R.L.; Chopp, M.; Roberts, C.; Liu, X.; Wei, M.; Nejad-Davarani, S.; Wang, X.; Zhang, Z.G. Stroke Increases Neural Stem Cells and Angiogenesis in the Neurogenic Niche of the Adult Mouse. PLoS ONE 2014, 9, e113972. [Google Scholar] [CrossRef] [Green Version]
- Cui, X.-P.; Xing, Y.; Chen, J.-M.; Dong, S.-W.; Ying, D.-J.; Yew, D.T. Wnt/beta-catenin is involved in the proliferation of hippocampal neural stem cells induced by hypoxia. Ir. J. Med Sci. 2010, 180, 387–393. [Google Scholar] [CrossRef] [PubMed]
- Piccin, D.; Morshead, C.M. Wnt Signaling Regulates Symmetry of Division of Neural Stem Cells in the Adult Brain and in Response to Injury. Stem Cells 2011, 29, 528–538. [Google Scholar] [CrossRef] [PubMed]
- Qi, C.; Zhang, J.; Chen, X.; Wan, J.; Wang, J.; Zhang, P.; Liu, Y. Hypoxia stimulates neural stem cell proliferation by increasing HIF-1α expression and activating Wnt/β-catenin signaling. Cell. Mol. Biol. 2017, 63, 12–19. [Google Scholar] [CrossRef]
- Chen, X.; Zhou, B.; Yan, T.; Wu, H.; Feng, J.; Chen, H.; Gao, C.; Peng, T.; Yang, D.; Shen, J. Peroxynitrite enhances self-renewal, proliferation and neuronal differentiation of neural stem/progenitor cells through activating HIF-1α and Wnt/β-catenin signaling pathway. Free. Radic. Biol. Med. 2018, 117, 158–167. [Google Scholar] [CrossRef]
- Zhang, X.; Zhu, C.; Luo, Q.; Dong, J.; Liu, L.; Li, M.; Zhu, H.; Ma, X.; Wang, J. Impact of siRNA targeting of β-catenin on differentiation of rat neural stem cells and gene expression of Ngn1 and BMP4 following in vitro hypoxic-ischemic brain damage. Mol. Med. Rep. 2016, 14, 3595–3601. [Google Scholar] [CrossRef] [Green Version]
- Shruster, A.; Ben-Zur, T.; Melamed, E.; Offen, D. Wnt Signaling Enhances Neurogenesis and Improves Neurological Function after Focal Ischemic Injury. PLoS ONE 2012, 7, e40843. [Google Scholar] [CrossRef]
- Laksitorini, M.; Yathindranath, V.; Xiong, W.; Hombach-Klonisch, S.; Miller, D.W. Modulation of Wnt/β-catenin signaling promotes blood-brain barrier phenotype in cultured brain endothelial cells. Sci. Rep. 2019, 9, 19718. [Google Scholar] [CrossRef] [Green Version]
- Menet, R.; Lecordier, S.; ElAli, A. Wnt Pathway: An Emerging Player in Vascular and Traumatic Mediated Brain Injuries. Front. Physiol. 2020, 11, 565667. [Google Scholar] [CrossRef] [PubMed]
- Martowicz, A.; Trusohamn, M.; Jensen, N.; Wisniewska-Kruk, J.; Corada, M.; Ning, F.C.; Kele, J.; Dejana, E.; Nyqvist, D. Endothelial β-Catenin Signaling Supports Postnatal Brain and Retinal Angiogenesis by Promoting Sprouting, Tip Cell Formation, and VEGFR (Vascular Endothelial Growth Factor Receptor) 2 Expression. Arter. Thromb. Vasc. Biol. 2019, 39, 2273–2288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peghaire, C.; Bats, M.-L.; Sewduth, R.; Jeanningros, S.; Jaspard-Vinassa, B.; Couffinhal, T.; Duplàa, C.; Dufourcq, P. Fzd7 (Frizzled-7) Expressed by Endothelial Cells Controls Blood Vessel Formation through Wnt/β-Catenin Canonical Signaling. Arter. Thromb. Vasc. Biol. 2016, 36, 2369–2380. [Google Scholar] [CrossRef] [Green Version]
- Hübner, K.; Cabochette, P.; Diéguez-Hurtado, R.; Wiesner, C.; Wakayama, Y.; Grassme, K.S.; Hubert, M.; Guenther, S.; Belting, H.-G.; Affolter, M.; et al. Wnt/β-catenin signaling regulates VE-cadherin-mediated anastomosis of brain capillaries by counteracting S1pr1 signaling. Nat. Commun. 2018, 9, 4860. [Google Scholar] [CrossRef] [Green Version]
- Corada, M.; Orsenigo, F.; Bhat, G.P.; Conze, L.L.; Breviario, F.; Cunha, S.I.; Claesson-Welsh, L.; Beznoussenko, G.V.; Mironov, A.A.; Bacigaluppi, M.; et al. Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier. Circ. Res. 2019, 124, 511–525. [Google Scholar] [CrossRef] [PubMed]
- De Ferrari, G.V.; E Avila, M.; Medina, M.; Pérez-Palma, E.; Bustos, B.; Alarcon, M. Wnt/β-Catenin Signaling in Alzheimer’s Disease. CNS Neurol. Disord.-Drug Targets 2014, 13, 745–754. [Google Scholar] [CrossRef]
- Hu, Y.; Chen, W.; Wu, L.; Jiang, L.; Liang, N.; Tan, L.; Liang, M.; Tang, N. TGF-β1 Restores Hippocampal Synaptic Plasticity and Memory in Alzheimer Model via the PI3K/Akt/Wnt/β-Catenin Signaling Pathway. J. Mol. Neurosci. 2019, 67, 142–149. [Google Scholar] [CrossRef] [PubMed]
- Folke, J.; Pakkenberg, B.; Brudek, T. Impaired Wnt Signaling in the Prefrontal Cortex of Alzheimer’s Disease. Mol. Neurobiol. 2018, 56, 873–891. [Google Scholar] [CrossRef]
- Ochalek, A.; Mihalik, B.; Avci, H.X.; Chandrasekaran, A.; Téglási, A.; Bock, I.; Giudice, M.L.; Táncos, Z.; Molnar, K.; Laszlo, L.; et al. Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation. Alzheimer’s Res. Ther. 2017, 9, 90. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Z.; Hartmann, H.; Do, V.M.; Abramowski, D.; Sturchler-Pierrat, C.; Staufenbiel, M.; Sommer, B.; Van De Wetering, M.; Clevers, H.; Saftig, P.; et al. Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nat. Cell Biol. 1998, 395, 698–702. [Google Scholar] [CrossRef]
- Tachibana, M.; Holm, M.-L.; Liu, C.-C.; Shinohara, M.; Aikawa, T.; Oue, H.; Yamazaki, Y.; Martens, Y.A.; Murray, M.; Sullivan, P.M.; et al. APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP. J. Clin. Investig. 2019, 129, 1272–1277. [Google Scholar] [CrossRef] [PubMed]
- Caricasole, A.; Copani, A.; Caraci, F.; Aronica, E.; Rozemuller, A.J.; Caruso, A.; Storto, M.; Gaviraghi, G.; Terstappen, G.C.; Nicoletti, F. Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Associated with Neuronal Degeneration in Alzheimer’s Brain. J. Neurosci. 2004, 24, 6021–6027. [Google Scholar] [CrossRef]
- Rojas, C.T.; Burgos, P.V.; Inestrosa, N.C. Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid-β (Aβ)42peptides. J. Neurochem. 2016, 139, 1175–1191. [Google Scholar] [CrossRef] [PubMed]
- Ly, P.T.; Wu, Y.; Zou, H.; Wang, R.; Zhou, W.; Kinoshita, A.; Zhang, M.; Yang, Y.; Cai, F.; Woodgett, J.; et al. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Investig. 2012, 123, 224–235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Su, Y.; Ryder, J.; Li, B.; Wu, X.; Fox, N.; Solenberg, P.; Brune, K.; Paul, S.; Zhou, Y.; Liu, F.; et al. Lithium, a Common Drug for Bipolar Disorder Treatment, Regulates Amyloid-β Precursor Protein Processing. Biochemistry 2004, 43, 6899–6908. [Google Scholar] [CrossRef] [PubMed]
- Fiorentini, A.; Rosi, M.C.; Grossi, C.; Luccarini, I.; Casamenti, F. Lithium Improves Hippocampal Neurogenesis, Neuropathology and Cognitive Functions in APP Mutant Mice. PLoS ONE 2010, 5, e14382. [Google Scholar] [CrossRef]
- Rojas, C.T.; Inestrosa, N.C. Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer’s disease in J20-APP transgenic and wild-type mice. J. Neurochem. 2018, 144, 443–465. [Google Scholar] [CrossRef] [Green Version]
- Plattner, F.; Angelo, M.; Giese, K.P. The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation. J. Biol. Chem. 2006, 281, 25457–25465. [Google Scholar] [CrossRef] [Green Version]
- Amaral, A.C.; Perez-Nievas, B.G.; Chong, M.S.T.; Gonzalez-Martinez, A.; Argente-Escrig, H.; Rubio-Guerra, S.; Commins, C.; Muftu, S.; Eftekharzadeh, B.; Hudry, E.; et al. Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation. iScience 2021, 24, 102058. [Google Scholar] [CrossRef]
- Wan, W.; Xia, S.; Kalionis, B.; Liu, L.; Li, Y. The Role of Wnt Signaling in the Development of Alzheimer’s Disease: A Potential Therapeutic Target? BioMed Res. Int. 2014, 2014, 301575. [Google Scholar] [CrossRef]
- Norwitz, N.G.; Mota, A.S.; Norwitz, S.G.; Clarke, K. Multi-Loop Model of Alzheimer Disease: An Integrated Perspective on the Wnt/GSK3β, α-Synuclein, and Type 3 Diabetes Hypotheses. Front. Aging Neurosci. 2019, 11, 184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vossel, K.A.; Xu, J.C.; Fomenko, V.; Miyamoto, T.; Suberbielle, E.; Knox, J.A.; Ho, K.; Kim, D.H.; Yu, G.-Q.; Mucke, L. Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. J. Cell Biol. 2015, 209, 419–433. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koh, S.-H.; Noh, M.Y.; Kim, S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase. Brain Res. 2008, 1188, 254–262. [Google Scholar] [CrossRef] [PubMed]
- Sellers, K.; Elliott, C.; Jackson, J.; Ghosh, A.; Ribe, E.; I Rojo, A.; Jarosz-Griffiths, H.; Watson, I.A.; Xia, W.; Semenov, M.; et al. Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil. Alzheimer’s Dement. 2018, 14, 306–317. [Google Scholar] [CrossRef] [PubMed]
- Purro, S.A.; Dickins, E.M.; Salinas, P.C. The Secreted Wnt Antagonist Dickkopf-1 Is Required for Amyloid β-Mediated Synaptic Loss. J. Neurosci. 2012, 32, 3492–3498. [Google Scholar] [CrossRef] [PubMed]
- Killick, R.; Ribe, E.; Al-Shawi, R.; Malik, B.; Hooper, C.; Fernandes, C.; Dobson, R.; Nolan, P.; Lourdusamy, A.; Furney, S.; et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway. Mol. Psychiatry 2014, 19, 88–98. [Google Scholar] [CrossRef] [PubMed]
- Zeng, Q.; Long, Z.; Feng, M.; Zhao, Y.; Luo, S.; Wang, K.; Wang, Y.; Yang, G.; He, G. Valproic Acid Stimulates Hippocampal Neurogenesis via Activating the Wnt/β-Catenin Signaling Pathway in the APP/PS1/Nestin-GFP Triple Transgenic Mouse Model of Alzheimer’s Disease. Front. Aging Neurosci. 2019, 11, 62. [Google Scholar] [CrossRef] [Green Version]
- Xuan, A.-G.; Pan, X.-B.; Wei, P.; Ji, W.-D.; Zhang, W.-J.; Liu, J.-H.; Hong, L.-P.; Chen, W.-L.; Long, D.-H. Valproic Acid Alleviates Memory Deficits and Attenuates Amyloid-β Deposition in Transgenic Mouse Model of Alzheimer’s Disease. Mol. Neurobiol. 2014, 51, 300–312. [Google Scholar] [CrossRef]
- Bian, H.; Bian, W.; Lin, X.; Ma, Z.; Chen, W.; Pu, Y. RNA Interference Silencing of Glycogen Synthase Kinase 3β Inhibites Tau Phosphorylation in Mice with Alzheimer Disease. Neurochem. Res. 2016, 41, 2470–2480. [Google Scholar] [CrossRef] [PubMed]
- Rockenstein, E.; Torrance, M.; Adame, A.; Mante, M.; Bar-On, P.; Rose, J.B.; Crews, L.; Masliah, E. Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3 Signaling Pathway in a Transgenic Model of Alzheimer’s Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation. J. Neurosci. 2007, 27, 1981–1991. [Google Scholar] [CrossRef] [PubMed]
- Cisternas, P.; Oliva, C.A.; Torres, V.I.; Barrera, D.P.; Inestrosa, N.C. Presymptomatic Treatment With Andrographolide Improves Brain Metabolic Markers and Cognitive Behavior in a Model of Early-Onset Alzheimer’s Disease. Front. Cell. Neurosci. 2019, 13, 295. [Google Scholar] [CrossRef] [PubMed]
- Vargas, J.Y.; Fuenzalida, M.; Inestrosa, N.C. In vivo Activation of Wnt Signaling Pathway Enhances Cognitive Function of Adult Mice and Reverses Cognitive Deficits in an Alzheimer’s Disease Model. J. Neurosci. 2014, 34, 2191–2202. [Google Scholar] [CrossRef] [Green Version]
- Zheng, R.; Zhang, Z.-H.; Chen, C.; Chen, Y.; Jia, S.-Z.; Liu, Q.; Ni, J.-Z.; Song, G.-L. Selenomethionine promoted hippocampal neurogenesis via the PI3K-Akt-GSK3β-Wnt pathway in a mouse model of Alzheimer’s disease. Biochem. Biophys. Res. Commun. 2017, 485, 6–15. [Google Scholar] [CrossRef] [PubMed]
- Varela-Nallar, L.; Rojas-Abalos, M.; Abbott, A.C.; Moya, E.A.; Iturriaga, R.; Inestrosa, N.C. Chronic hypoxia induces the activation of the Wnt/β-catenin signaling pathway and stimulates hippocampal neurogenesis in wild-type and APPswe-PS1ΔE9 transgenic mice in vivo. Front. Cell. Neurosci. 2014, 8, 17. [Google Scholar] [CrossRef] [Green Version]
- Huang, M.; Liang, Y.; Chen, H.; Xu, B.; Chai, C.; Xing, P. The Role of Fluoxetine in Activating Wnt/β-Catenin Signaling and Repressing β-Amyloid Production in an Alzheimer Mouse Model. Front. Aging Neurosci. 2018, 10, 164. [Google Scholar] [CrossRef] [Green Version]
- Aghaizu, N.D.; Jin, H.; Whiting, P.J. Dysregulated Wnt Signalling in the Alzheimer’s Brain. Brain Sci. 2020, 10, 902. [Google Scholar] [CrossRef]
- Ma, Q.; Zhao, Z.; Sagare, A.P.; Wu, Y.; Wang, M.; Owens, N.C.; Verghese, P.B.; Herz, J.; Holtzman, D.M.; Zlokovic, B.V. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Mol. Neurodegener. 2018, 13, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Daneman, R.; Agalliu, D.; Zhou, L.; Kuhnert, F.; Kuo, C.J.; Barres, B.A. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. Proc. Natl. Acad. Sci. USA 2009, 106, 641–646. [Google Scholar] [CrossRef] [Green Version]
- Cisternas, P.; Zolezzi, J.M.; Martinez, M.; Torres, V.I.; Wong, G.W.; Inestrosa, N.C. Wnt-induced activation of glucose metabolism mediates the in vivo neuroprotective roles of Wnt signaling in Alzheimer disease. J. Neurochem. 2019, 149, 54–72. [Google Scholar] [CrossRef] [Green Version]
- Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer. Nat. Cell Biol. 2005, 434, 843–850. [Google Scholar] [CrossRef]
- Guan, R.; Zhang, X.; Guo, M. Glioblastoma stem cells and Wnt signaling pathway: Molecular mechanisms and therapeutic targets. Chin. Neurosurg. J. 2020, 6, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Davis, M.; O’Connell, T.; Johnson, S.; Cline, S.; Merikle, E.; Martenyi, F.; Simpson, K.N. Estimating Alzheimer’s Disease Progression Rates from Normal Cognition through Mild Cognitive Impairment and Stages of Dementia. Curr. Alzheimer Res. 2018, 15, 777–788. [Google Scholar] [CrossRef] [PubMed]
- Haile, W.B.; Wu, J.; Echeverry, R.; Wu, F.; An, J.; Yepes, M. Tissue-Type Plasminogen Activator has a Neuroprotective Effect in the Ischemic Brain Mediated by Neuronal TNF-α. Br. J. Pharmacol. 2011, 32, 57–69. [Google Scholar] [CrossRef]
- Kim, J.S. tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use? J. Stroke 2019, 21, 160–174. [Google Scholar] [CrossRef] [PubMed]
- Schneider, L.S.; Dagerman, K.S.; Higgins, J.; McShane, R. Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease. Arch. Neurol. 2011, 68, 991–998. [Google Scholar] [CrossRef]
- Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer’s disease: Clinical trials and drug development. Lancet Neurol. 2010, 9, 702–716. [Google Scholar] [CrossRef]
- Hefti, F.; Goure, W.F.; Jerecic, J.; Iverson, K.S.; Walicke, P.A.; Krafft, G.A. The case for soluble Aβ oligomers as a drug target in Alzheimer’s disease. Trends Pharmacol. Sci. 2013, 34, 261–266. [Google Scholar] [CrossRef]
- Rasool, S.; Martínez-Coria, H.; Wu, J.W.; LaFerla, F.; Glabe, C.G. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. J. Neurochem. 2013, 126, 473–482. [Google Scholar] [CrossRef] [Green Version]
- Xiao, C.; Davis, F.J.; Chauhan, B.C.; Viola, K.L.; Lacor, P.N.; Velasco, P.T.; Klein, W.L.; Chauhan, N.B. Brain Transit and Ameliorative Effects of Intranasally Delivered Anti-Amyloid-β Oligomer Antibody in 5XFAD Mice. J. Alzheimer’s Dis. 2013, 35, 777–788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tucker, S.; Möller, C.; Tegerstedt, K.; Lord, A.; Laudon, H.; Sjödahl, J.; Söderberg, L.; Spens, E.; Sahlin, C.; Waara, E.R.; et al. The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-β Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice. J. Alzheimer’s Dis. 2014, 43, 575–588. [Google Scholar] [CrossRef]
- Izzo, N.J.; Staniszewski, A.; To, L.; Fà, M.; Teich, A.; Saeed, F.; Wostein, H.; Walko, T.; Vaswani, A.; Wardius, M.; et al. Alzheimer’s Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits. PLoS ONE 2014, 9, e111898. [Google Scholar] [CrossRef] [PubMed]
- Izzo, N.; Xu, J.; Zeng, C.; Kirk, M.J.; Mozzoni, K.; Silky, C.; Rehak, C.; Yurko, R.; Look, G.; Rishton, G.; et al. Alzheimer’s Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity. PLoS ONE 2014, 9, e111899. [Google Scholar] [CrossRef] [PubMed]
- Blurton-Jones, M.; Kitazawa, M.; Martínez-Coria, H.; Castello, N.A.; Müller, F.-J.; Loring, J.; Yamasaki, T.R.; Poon, W.; Green, K.N.; LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA 2009, 106, 13594–13599. [Google Scholar] [CrossRef] [Green Version]
- Ager, R.R.; Davis, J.L.; Agazaryan, A.; Benavente, F.; Poon, W.; LaFerla, F.M.; Blurton-Jones, M. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer’s disease and neuronal loss. Hippocampus 2015, 25, 813–826. [Google Scholar] [CrossRef] [Green Version]
- Boese, A.C.; Hamblin, M.H.; Lee, J.-P. Neural stem cell therapy for neurovascular injury in Alzheimer’s disease. Exp. Neurol. 2020, 324, 113112. [Google Scholar] [CrossRef]
- Rothstein, J.D.; Patel, S.A.; Regan, M.R.; Haenggeli, C.; Huang, Y.H.; Bergles, D.E.; Jin, L.; Hoberg, M.D.; Vidensky, S.; Chung, D.S.; et al. β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433, 73–77. [Google Scholar] [CrossRef]
- Zumkehr, J.; Rodriguez-Ortiz, C.J.; Cheng, D.; Kieu, Z.; Wai, T.; Hawkins, C.; Kilian, J.; Lim, S.L.; Medeiros, R.; Kitazawa, M. Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer’s disease. Neurobiol. Aging 2015, 36, 2260–2271. [Google Scholar] [CrossRef] [Green Version]
- Brann, D.W.; Dhandapani, K.; Wakade, C.; Mahesh, V.B.; Khan, M. Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications. Steroids 2007, 72, 381–405. [Google Scholar] [CrossRef] [Green Version]
- Ji, Y.-F.; Xu, S.-M.; Zhu, J.; Wang, X.-X.; Shen, Y. Insulin increases glutamate transporter GLT1 in cultured astrocytes. Biochem. Biophys. Res. Commun. 2011, 405, 691–696. [Google Scholar] [CrossRef] [PubMed]
- Frizzo, M.E.D.S.; Dall’Onder, L.P.; Dalcin, K.B.; Souza, D. Riluzole Enhances Glutamate Uptake in Rat Astrocyte Cultures. Cell. Mol. Neurobiol. 2004, 24, 123–128. [Google Scholar] [CrossRef]
- Etminan, M.; Gill, S.; Samii, A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: Systematic review and meta-analysis of observational studies. BMJ 2003, 327, 128. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, J.; Tan, L.; Wang, H.-F.; Tan, C.-C.; Meng, X.-F.; Wang, C.; Tang, S.-W.; Yu, J.-T. Anti-Inflammatory Drugs and Risk of Alzheimer’s Disease: An Updated Systematic Review and Meta-Analysis. J. Alzheimer’s Dis. 2015, 44, 385–396. [Google Scholar] [CrossRef] [PubMed]
- Miguel-Álvarez, M.; Santos-Lozano, A.; Sanchis-Gomar, F.; Fiuza-Luces, C.; Pareja-Galeano, H.; Garatachea, N.; Lucia, A. Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect. Drugs Aging 2015, 32, 139–147. [Google Scholar] [CrossRef] [PubMed]
- Butchart, J.; Brook, L.; Hopkins, V.; Teeling, J.; Püntener, U.; Culliford, D.; Sharples, R.; Sharif, S.; McFarlane, B.; Raybould, R.; et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology 2015, 84, 2161–2168. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duffy, J.P.; Harrington, E.M.; Salituro, F.G.; Cochran, J.E.; Green, J.; Gao, H.; Bemis, G.W.; Evindar, G.; Galullo, V.P.; Ford, P.J.; et al. The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor. ACS Med. Chem. Lett. 2011, 2, 758–763. [Google Scholar] [CrossRef] [Green Version]
- Dong, Y.; Li, X.; Cheng, J.; Hou, L. Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target? Int. J. Mol. Sci. 2019, 20, 558. [Google Scholar] [CrossRef] [Green Version]
- Cummings, J.; Aisen, P.; Lemere, C.; Atri, A.; Sabbagh, M.; Salloway, S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimer’s Res. Ther. 2021, 13, 1–3. [Google Scholar] [CrossRef]
- Bastrup, J.; Hansen, K.H.; Poulsen, T.B.; Kastaniegaard, K.; Asuni, A.A.; Christensen, S.; Belling, D.; Helboe, L.; Stensballe, A.; Volbracht, C. Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer’s Disease. J. Alzheimer’s Dis. 2021, 79, 249–265. [Google Scholar] [CrossRef]
- Knopman, D.S.; Jones, D.T.; Greicius, M.D. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December. Alzheimer’s Dement. 2021, 17, 696–701. [Google Scholar] [CrossRef]
- Gao, K.; Zhang, T.; Wang, F.; Lv, C. Therapeutic Potential of Wnt-3a in Neurological Recovery after Spinal Cord Injury. Eur. Neurol. 2019, 81, 197–204. [Google Scholar] [CrossRef]
- Jope, R.S.; Cheng, Y.; Lowell, J.; Worthen, R.; Sitbon, Y.H.; Beurel, E. Stressed and Inflamed, Can GSK3 Be Blamed? Trends Biochem. Sci. 2017, 42, 180–192. [Google Scholar] [CrossRef] [Green Version]
- Kawamoto, E.; Gleichmann, M.; Yshii, L.; Lima, L.D.S.; Mattson, M.; Scavone, C. Effect of activation of canonical Wnt signaling by the Wnt-3a protein on the susceptibility of PC12 cells to oxidative and apoptotic insults. Braz. J. Med. Biol. Res. 2012, 45, 58–67. [Google Scholar] [CrossRef] [Green Version]
- Iozzi, S.; Remelli, R.; Lelli, B.; Diamanti, D.; Pileri, S.; Bracci, L.; Roncarati, R.; Caricasole, A.; Bernocco, S. Functional Characterization of a Small-Molecule Inhibitor of the DKK1-LRP6 Interaction. ISRN Mol. Biol. 2012, 2012, 823875. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ling, S.; Birnbaum, Y.; Nanhwan, M.K.; Thomas, B.; Bajaj, M.; Li, Y.; Li, Y.; Ye, Y. Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN) crosstalk via microRNA interference in the diabetic heart. Basic Res. Cardiol. 2013, 108, 352. [Google Scholar] [CrossRef] [PubMed]
- Ross, S.P.; Baker, K.E.; Fisher, A.; Hoff, L.; Pak, E.S.; Murashov, A.K. miRNA-431 Prevents Amyloid-β-Induced Synapse Loss in Neuronal Cell Culture Model of Alzheimer’s Disease by Silencing Kremen. Front. Cell. Neurosci. 2018, 12, 87. [Google Scholar] [CrossRef] [Green Version]
- Silva-Alvarez, C.; Arrázola, M.S.; A Godoy, J.; Ordenes, D.; Inestrosa, N.C. Canonical Wnt signaling protects hippocampal neurons from Aβ oligomers: Role of non-canonical Wnt-5a/Ca2+ in mitochondrial dynamics. Front. Cell. Neurosci. 2013, 7, 97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, J.; Long, Z.; Li, Y.; Luo, M.; Luo, S.; He, G. Alteration of the Wnt/GSK3β/β-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer’s disease model. Int. J. Mol. Med. 2019, 44, 313–323. [Google Scholar] [CrossRef] [PubMed]
- Vallée, A.; Vallée, J.-N.; Guillevin, R.; Lecarpentier, Y. Riluzole: A therapeutic strategy in Alzheimer’s disease by targeting the WNT/β-catenin pathway. Aging 2020, 12, 3095–3113. [Google Scholar] [CrossRef] [PubMed]
- Farías, G.G.; Godoy, J.A.; Vázquez, M.C.; Adani, R.; Meshulam, H.; Avila, J.; Amitai, G.; Inestrosa, N.C. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from β-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 2005, 18, 176–183. [Google Scholar] [CrossRef]
- Wiciński, M.; Socha, M.; Malinowski, B.; Wódkiewicz, E.; Walczak, M.; Górski, K.; Słupski, M.; Pawlak-Osińska, K. Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events. Int. J. Mol. Sci. 2019, 20, 1050. [Google Scholar] [CrossRef] [Green Version]
- Inestrosa, N.C.; Godoy, J.A.; Vargas, J.Y.; Arrázola, M.S.; Rios, J.A.; Carvajal, F.J.; Serrano, F.G.; Farías, G.G. Nicotine Prevents Synaptic Impairment Induced by Amyloid-β Oligomers through α7-Nicotinic Acetylcholine Receptor Activation. Neuromolecular Med. 2013, 15, 549–569. [Google Scholar] [CrossRef]
- Echuang, D.-M.; Ewang, Z.; Echiu, C.-T. GSK-3 as a Target for Lithium-Induced Neuroprotection against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. Front. Mol. Neurosci. 2011, 4, 15. [Google Scholar] [CrossRef] [Green Version]
- Tümpel, S.; Rudolph, K.L. Quiescence: Good and Bad of Stem Cell Aging. Trends Cell Biol. 2019, 29, 672–685. [Google Scholar] [CrossRef] [Green Version]
- Ji, Y.-B.; Gao, Q.; Tan, X.-X.; Huang, X.-W.; Ma, Y.-Z.; Fang, C.; Wang, S.-N.; Qiu, L.-H.; Cheng, Y.-X.; Guo, F.-Y.; et al. Lithium alleviates blood-brain barrier breakdown after cerebral ischemia and reperfusion by upregulating endothelial Wnt/β-catenin signaling in mice. Neuropharmacology 2021, 186, 108474. [Google Scholar] [CrossRef] [PubMed]
- Mohamadianinejad, S.E.; Majdinasab, N.; Sajedi, S.A.; Abdollahi, F.; Moqaddam, M.M.; Sadr, F. The Effect of Lithium in Post-Stroke Motor Recovery. Clin. Neuropharmacol. 2014, 37, 73–78. [Google Scholar] [CrossRef]
- Clinical Trials. Available online: clinicaltrials.gov (accessed on 27 July 2021).
- Doeppner, T.R.; Kaltwasser, B.; Sanchez-Mendoza, E.H.; Caglayan, A.B.; Bähr, M.; Hermann, D.M. Lithium-induced neuroprotection in stroke involves increased miR-124 expression, reduced RE1-silencing transcription factor abundance and decreased protein deubiquitination by GSK3β inhibition-independent pathways. Br. J. Pharmacol. 2017, 37, 914–926. [Google Scholar] [CrossRef] [Green Version]
- Pluta, R.; Ułamek-Kozioł, M.; Czuczwar, S.J. Neuroprotective and Neurological/Cognitive Enhancement Effects of Curcumin after Brain Ischemia Injury with Alzheimer’s Disease Phenotype. Int. J. Mol. Sci. 2018, 19, 4002. [Google Scholar] [CrossRef] [Green Version]
- Pluta, R.; Bogucka-Kocka, A.; Ułamek-Kozioł, M.; Furmaga-Jabłońska, W.; Januszewski, S.; Brzozowska, J.; Jabłoński, M.; Kocki, J. Review paper Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: Is there a role for curcumin? Folia Neuropathol. 2015, 2, 89–99. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Forouzanfar, F.; Read, M.I.; Barreto, G.E.; Sahebkar, A. Neuroprotective effects of curcumin through autophagy modulation. IUBMB Life 2020, 72, 652–664. [Google Scholar] [CrossRef] [PubMed]
- Tiwari, S.K.; Agarwal, S.; Tripathi, A.; Chaturvedi, R.K. Bisphenol-A Mediated Inhibition of Hippocampal Neurogenesis Attenuated by Curcumin via Canonical Wnt Pathway. Mol. Neurobiol. 2016, 53, 3010–3029. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kriska, J.; Hermanova, Z.; Knotek, T.; Tureckova, J.; Anderova, M. On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease. Int. J. Mol. Sci. 2021, 22, 9689. https://doi.org/10.3390/ijms22189689
Kriska J, Hermanova Z, Knotek T, Tureckova J, Anderova M. On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease. International Journal of Molecular Sciences. 2021; 22(18):9689. https://doi.org/10.3390/ijms22189689
Chicago/Turabian StyleKriska, Jan, Zuzana Hermanova, Tomas Knotek, Jana Tureckova, and Miroslava Anderova. 2021. "On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease" International Journal of Molecular Sciences 22, no. 18: 9689. https://doi.org/10.3390/ijms22189689